Rhythm Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2015
Net Income	-273.87	-184.68	-181.12	-69.61	-134	-140.73	Upgrade
Depreciation & Amortization	1.71	1.76	1.67	1.16	0.69	0.83	Upgrade
Share-Based Compensation	33.94	32.55	19.83	20.8	17.46	11.88	Upgrade
Other Operating Activities	97.75	14.21	-13.81	-98.35	-6.13	5.27	Upgrade
Operating Cash Flow	-140.47	-136.16	-173.43	-146	-121.98	-122.75	Upgrade
Capital Expenditures	0	-0.05	-0.28	99.57	-0.21	-3.39	Upgrade
Acquisitions	-41.15	-5.67	0	0	0	0	Upgrade
Change in Investments	47.07	0.05	32.31	-163.73	158.75	-24.59	Upgrade
Other Investing Activities	-	-	-4	2	-	-	Upgrade
Investing Cash Flow	5.92	-5.67	28.03	-62.16	158.53	-27.97	Upgrade
Share Issuance / Repurchase	63.2	57.4	141.49	166.48	2.01	163.47	Upgrade
Debt Issued / Paid	24.37	24.37	72.34	0	0	0	Upgrade
Other Financing Activities	-8.83	-7.4	-	-	-	-	Upgrade
Financing Cash Flow	78.74	74.37	213.83	166.48	2.01	163.47	Upgrade
Exchange Rate Effect	-0.3	-0.14	0	0	0	0	Upgrade
Net Cash Flow	-56.1	-67.6	68.43	-41.68	38.56	12.75	Upgrade
Free Cash Flow	-140.47	-136.2	-173.71	-46.44	-122.19	-126.14	Upgrade
Free Cash Flow Margin	-152.80%	-175.91%	-734.87%	-1472.32%	-	-	Upgrade
Free Cash Flow Per Share	-2.34	-2.36	-3.33	-0.94	-2.77	-3.46	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).